In this review, we comprehensively examine the role of the MEK pathway in carcinogenesis and its therapeutic potential in cancer patients, with a focus on MEKi. We describe the clinical perspectives of MEKi in the two main models of Ras–ERK driven tumors, BRAF-mutant (“addicted” to the ...
Tumours manage to survive the ablation of mutant KRAS, despite the development of KRAS-targeted drugs. Here we describe that inhibition of mutant KRAS promotes MEK nuclear localization as an alternative mechanism of KRAS-targeted drugs resistance. Tissue
Frontiers in BiologyPark JI: Growth arrest signaling of the Raf/MEK/ERK pathway in cancer. Front Biol (Beijing) 9: 95-103, 2014.Park JI. Growth arrest signaling of the Raf/MEK/ERK pathway in cancer. Front Biol (Beijing). 2014; 9: 95-103....
Full Name mitogen-activated protein kinase kinase 1 Calculated Molecular Weight 43 kDa GenBank Accession Number BC139729 Gene Symbol MEK1 Gene ID (NCBI) 5604 ENSEMBL Gene ID ENSG00000169032 RRID AB_2881242 Conjugate Unconjugated Form Liquid Purification Method Antigen affinity purification UNIPROT ID ...
Testicular germ cell tumours (TGCT) represent the most common malignancies in young males. Whereas in 1970s, the survival rate in patients with metastatic testicular tumours was only 5%, these days, 80% of the patients treated by modern chemotherapy will
Eukaryotic initiation translation factor 3 subunit h (EIF3H) plays critical roles in regulating translational initiation and predicts poor cancer prognosis, but the mechanism underlying EIF3H tumorigenesis remains to be further elucidated. Here, we repor
miR-34a-5p functions as a tumor suppressor in head and neck squamous cell cancer progression by targeting Flotillin-2. Authors - Xiang Li View Article mouse,human WB World J Gastroenterol TATA-box-binding protein-associated factor 15 is a novel biomarker that promotes cell proliferation and migrat...
and MAPK). These signaling cascades are often dysregulated in human cancer cells. Many small molecule inhibitors targeting various component of these cascades are moving quickly from bench to bedside [2–4]. For instance, vemurafenib is the first B-RAF inhibitor that received FDA approval in 2011...
Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer Murugan Kalimutho, Debottam Sinha, Deepak Mittal, Sriganesh Srihari, Devathri Nanayakkara, Shagufta Shafique, Prahlad Raninga, Purba Nag, Kate Pa...
Distant metastasis is the leading cause of cancer-related mortality, and achieving survival benefits through advancements in systemic therapy remains challenging. Mast cells play a dual role in shaping the tumor microenvironment (TME) and influencing dis